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In order to demonstrate its highest political 
commitment to the fight against HIV and AIDS 
and to militate against the harmful socioeconomic 
impact that communities have been subjected to, the 
National Program to Fight HIV/AIDS in Tajikistan has 
requested the donor communities to provide technical 
assistance for the modeling of an optimized investment 
approach for Tajikistan in the context of sustainable 
financing of national HIV responses.
As the world economic landscape changes, so too 
does the HIV funding landscape. Donor funding has 
stagnated, and the limited resources available require 
more emphasis on value for money: funds spent for 
the greatest impact and in the most efficient way. At 
the same time, Tajikistan has made some progress 
on increasing the domestic funding led by H.E the 
President of Tajikistan who endorsed the establishment 
of the “National HIV/AIDS Fund” in September 2014. 
With joint and concerted efforts of all country partners 
and stakeholders, the National Program to Fight HIV/
AIDS has succeeded to contain the epidemic at a 
concentrated stage and to reduce the prevalence among 
key affected populations. More people living with 
HIV are on treatment and care than ever before, more 
people know their status and there are indications that 
the HIV incidence is starting to decline. However, due 
to scarcity of domestic and donor funding the National 
Program has to weigh all existing and potential 
resources in order to continue fighting with this deadly 
disease and eliminates it ultimately.
Considering the upcoming application to the Global 
Fund to Fight AIDS, Tuberculosis and Malaria, this 
document provides the requisite framework for 
choosing a well-balanced allocation for funding in the 
quest to optimize impact and serves with its findings 
and recommendations as a key document to achieve 
goals and targets of the newly developed National HIV 
Strategic Plan for 2015-2017. 
I wish on behalf of the Ministry of Health and Social 
Protection of the Republic of Tajikistan to pledge the 
Government’s determination to end the epidemic threat 
of AIDS. I am convinced that it is achievable if we all 
get resolved and fight the suffering that this disease 
continue to inflict on our people and communities in 
national and international solidarity.
Mr. Nusratullo Salimzoda
Minister, Ministry of Health and Social Protection of the 
Republic of Tajikistan
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Foreword
{  There is one year left to account for final 
achievements against the MDG6 targets: to halt and 
begin to reverse the spread of HIV, and to provide 
universal access to ART to all those in need; there 
is one year to go until UN member states will agree 
on the post-2015 agenda and the new SDGs which 
will most likely re-enforce the UNAIDS Getting-to-
Zero Strategy1 and call for ending the HIV/AIDS 
epidemic by 2030. 
{  While considerable progress has been made, 
Tajikistan is still struggling to reverse the 
spread of HIV, key populations at higher risk 
for HIV exposure still face discrimination and 
criminalization, and ART coverage is well below the 
MDG6 target. 
{  As a low-income country with the lowest GDP 
per capita in the region, Tajikistan’s national HIV 
response is highly dependent on external funding, 
mainly provided through the Global Fund to Fight 
AIDS, TB and Malaria (GF). Demands are increasing 
for higher domestic funding as pre-condition for 
external support, and while there is a renewed 
commitment to scale up the HIV response under the 
new National HIV/AIDS Response Strategy 2015-
2017 of the Republic of Tajikistan2 external funding is 
rather stagnating at current levels. 
{  This document aims to contribute to the 
development of sustainable financing strategies for 
the national HIV response in the short-, mid-, and 
long-term perspective by modelling the impact of 
alternative investment approaches. As part of the 
short-term contribution, the document provides a 
rational for improved allocative efficiency that can be 
1  Joint United Nations Programme on HIV/AIDS. Getting to Zero: 2011–2015 
strategy. Geneva: Joint United Nations Programme on HIV/AIDS; 2010.
2  Republic of Tajikistan. National strategy against the HIV/AIDS epidemic in 
the Republic of Tajikistan (2015-2017). Dushanbe: National Coordination 
Committee to Combat HIV/AIDS, Tuberculosis and Malaria in the 
Republic of Tajikistan; 2014.
used for the GF concept note currently prepared by 
Tajikistan under the GF New Funding Model (NFM). 
{  For the modelling, the following key questions of 
primary relevance for investment decisions related 
to the national HIV response were identified and 
addressed through modelling three investment 
scenarios using 2013 as the reference year: 
 P  What is the HIV epidemic in Tajikistan likely to 
look like if the response continues unchanged? 
And what will be the return on investment by 
2020? 
Scenario 1: Continue with the current 
investment allocations and current budget 
ceiling
	 P  Can be more achieved with the same amount 
of resources, and how? What would then be the 
return on investment by 2020? 
Scenario 2: Continue with optimised 
investment allocations and current budget 
ceiling
 P  Using optimized efficiencies, what would need 
to be done and how much would it cost to 
achieve universal coverage of the key prevention 
and treatment services? What would then be the 
return on investment by 2020? 
Scenario 3: Continue by scaling up to 
universal coverage of essential HIV prevention 
and treatment services
 P  For all three scenarios, what would be the long-
term impact by 2030?
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Executive summary
The model results suggest:
{  Maintaining the current investment allocations 
and budget level should be the absolute minimum 
target in order not to fall back behind the moderate 
impact the national HIV response has achieved so 
far. 
{  Technical and allocative efficiencies can be 
improved and recommendations are provided. 
However, the current budget ceiling is too low to 
achieve universal coverage of essential HIV services. 
Due to the resulting service rationalization, only 
improving efficiencies without addressing the 
overall budget constraints (scenario 2) will not 
be sufficient in Tajikistan for ‘Getting-to-Zero’, 
achieving MDG6 targets, ending the HIV/AIDS 
epidemic by 2030 and fulfilling the basic rights for 
access to essential HIV services for those in need.
{  To achieve these goals and targets, and particularly 
to fulfil the basic right for access to essential HIV 
services (scenario 3) the overall investment until 
2020 would need to be increased by some 25%.
{  As return on this investment, around 29,000 new 
HIV infections would be averted between 2014 and 
2030 under scenario 3 using the ‘test and treat’3 
3  Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV 
elimination by ‘test and treat’ in hyperendemic settings. AIDS. 
2010;24(5):729-35.
approach (around 27,000 using the WHO 2013 
ART guideline4, 26,500 using current national ART 
guideline). Scenario 2 and 1 avert significantly 
lower numbers of HIV infections, approximately 
20,000 and 16,000, respectively.
{  In addition, around 323,000 DALYs would be 
averted between 2014 and 2030 under scenario 3 
using the ‘test and treat’ approach (314,000 using 
the WHO 2013 ART guideline, 302,000 using 
current national ART guideline). Scenario 2 and 
1 avert significantly less DALYs, approximately 
119,000 and 78,000.
{  Detailed information about the mathematical 
model used is provided in the Annex.
4  World Health Organisation. Consolidated guidelines on the use 
of antiretroviral drugs for treating and preventing HIV infection. 
Recommendations for a public health approach. Geneva: World Health 
Organisation; 2013.
The key message of this report: 
With a moderate increase of the investment volume until 2020 combined with an optimized 
investment allocation the national HIV response in Tajikistan can be brought on a trajectory which 
fulfils the basic rights to access to essential HIV services for those in need and makes ending the 
epidemic threat of HIV/AIDS in Tajikistan a realistic goal if an environment without stigma and 
discrimination is provided so that services available will be accepted and used by the affected 
communities.
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The HIV response is heavily dependent 
on international sources
{  The Republic of Tajikistan is the only remaining 
low-income country of the CIS; however, it has seen 
a GDP per capita growth from $ 139 in 2000 to  
$ 1,305 in 20135,6. 
{  The Government provides some funding for the 
HIV/AIDS National Programme from the national 
budget but expenditures from public funds were 
mainly spent on recurrent costs, namely human 
resources and costs of public health care facilities 
and organisations. Public funds constituted 
around 24% of the total HIV/AIDS expenditure in 
Tajikistan in 20137. 
{  Main funding for the national HIV response comes 
from international sources, particularly the Global 
Fund to Fight AIDS, Tuberculosis and Malaria (GF).
The current HIV response is 
insufficient to meet all commitments
{  Public sector health care personnel is insufficiently 
trained and retained in Tajikistan; this is one of the 
major constraints in scaling up HIV/AIDS care and 
treatment.
{  Insufficient integration of HIV services into 
primary health care makes a decentralized response 
and scale-up difficult.
{  Considerable benefits could be achieved from 
scaling up OST for people who inject drugs 
(PWID), as this group has the highest HIV 
5  All financial values in this report, including tables and figures, are 
expressed in United States dollars.
6  The World Bank. World Development Indicators.
7  Republic of Tajikistan. Tajikistan National AIDS Spending Assessment: 
2012-2013. Dushanbe: National Coordination Committee to Combat HIV/
AIDS, Tuberculosis and Malaria in the Republic of Tajikistan, Ministry of 
Health of the Republic of Tajikistan; 2014.
prevalence in Tajikistan. Failure to control the 
epidemic among PWID will lead to onward 
infections in other groups, eventually including 
low-risk males and females. With this in mind, it is 
essential that OST moves beyond its pilot phase to 
being a fully integrated intervention. 
{  According to a combination of empirical data 
and model-based estimates, HIV prevalence and 
incidence in Tajikistan are stabilising or slightly 
declining.
{  The marked labour migration from Tajikistan is 
largely caused by difficult economic conditions in 
Tajikistan. Migration to and from areas of higher 
HIV prevalence increases the risk of HIV infection 
and makes specific interventions more difficult.
{  Overall, the national HIV response faces challenges 
to fulfil the target of universal coverage of essential 
HIV prevention and treatment services, and to halt 
or even substantially reduce the HIV epidemic in 
Tajikistan.
International aid is unlikely to 
increase
{  The recent global economic crisis has diminished 
the prospects of growing or even stable 
international funding for national HIV responses in 
the region.
{  Countries are coming under increased pressure to 
reduce dependencies on external funding and to 
transition to domestic financing mechanisms.
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1.  Why is this document needed?
Objectives 
{  To provide model estimates of future epidemic 
trajectories in the context of the development of 
an HIV/AIDS investment case and sustainable 
financing strategies of the national response for 
Tajikistan under three scenarios:
 P  Scenario 1: Continue with the current 
investment allocations and current budget 
ceiling;
 P  Scenario 2: Continue with optimised investment 
allocations and current budget ceiling;
 P  Scenario 3: Continue by scaling up to universal 
coverage of essential HIV prevention and 
treatment services. 
 2013 was used as the reference year.
{  To estimate and compare the programme costs and 
the impact (‘return on investment’ expressed in new 
HIV infections averted and DALYs averted) of the 
three scenarios above in the mid-term (2020) and 
long-term (2030) perspective under consideration 
of short-term objectives such as the development 
of GF concept note under the NFM, and long-term 
objectives such as the UNAIDS ‘Getting to Zero’ 
goals8, ‘Together we will end AIDS’ campaign9 and 
the proposed target of ending the AIDS epidemic by 
2030 under the SDGs10 11.
8  Joint United Nations Programme on HIV/AIDS. Getting to Zero: 
2011–2015 strategy. Geneva: Joint United Nations Programme on HIV/
AIDS; 2010.
9  Joint United Nations Programme on HIV/AIDS. Together we will end 
AIDS campaign.
10  Open Working Group of the General Assembly on Sustainable 
Development Goals. Introduction and proposed goals and targets on 
sustainable development for the post 2015 agenda. New York: Opening 
Working Group; 2014.
11  Joint United Nations Programme on HIV/AIDS. Fast-Track: ending the 
AIDS epidemic by 2030. Geneva: Joint United Nations Programme on 
HIV/AIDS; 2014.
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The national HIV response has been 
dependent on international aid
{  National AIDS Spending Assessments (NASAs) 
were used to assess HIV/AIDS expenditure in 
Tajikistan12,13,14.
{  Over the past several years funding for HIV/AIDS 
in Tajikistan has seen patterns of increase and 
decrease, with around $ 6.2 million available in 
2008, $ 15.4 million in 2011, $ 12.7 million in 2012 
and $ 14.1 million in 2013 (figure 1).
12  Republic of Tajikistan. Tajikistan National AIDS Spending Assessment: 
2008-2009. Dushanbe: National Coordination Committee to Combat HIV/
AIDS, Tuberculosis and Malaria in the Republic of Tajikistan, Ministry of 
Health of the Republic of Tajikistan; 2010.
13  Republic of Tajikistan. Tajikistan National AIDS Spending Assessment: 
2010-2011. Dushanbe: National Coordination Committee to Combat HIV/
AIDS, Tuberculosis and Malaria in the Republic of Tajikistan, Ministry of 
Health of the Republic of Tajikistan; 2012.
14  Republic of Tajikistan. Tajikistan National AIDS Spending Assessment: 
2012-2013. Dushanbe: National Coordination Committee to Combat HIV/
AIDS, Tuberculosis and Malaria in the Republic of Tajikistan, Ministry of 
Health of the Republic of Tajikistan; 2014.
{  HIV/AIDS funding from the international 
community has more than doubled since 2008. 
{  Domestic investments in HIV/AIDS are low 
compared to what is needed and compared to the 
international investment. 
The national HIV response depends largely 
on external funding, but Government 
expenditure is slowly increasing
{  GF has been the major donor. For the 2014-2016 
period, the GF has recently allocated $ 24.7 million 
for HIV grants in Tajikistan15; the annual average of 
$ 8.2 million is still lower than the GF investment at 
its peak in 2010 ($ 9.3 million), but higher than in 
the previous three years.
15  Global Fund to Fight AIDS, Tuberculosis and Malaria. Global Fund 
Country Allocations: 2014-2016. Geneva: Global Fund to Fight AIDS, 
Tuberculosis and Malaria; 2014.
Figure 1: HIV funding in Tajikistan in 2012 and 2013 by source*
$0 
$ 2,000,000 
$ 4,000,000 
$ 6,000,000 
$ 8,000,000 
2012 2013 
Government 2,569,872 3,363,877 
Out of pocket 342,288 349,699 
Global Fund 7,275,123 7,094,846 
Other international 2,528,641 3,269,471 
Funding
TOTAL $ 12,715,924 $ 14,077,893
* Source: Republic of Tajikistan. Tajikistan National AIDS Spending Assessment: 2012-2013. Dushanbe: 2014, and UNDP Tajikistan.
2.   How much is spent? Where does the 
money come from?
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Breakdown of funding by programme 
components
{  Prevention has been the largest funding category, 
comprising approximately 50% of HIV/AIDS 
spending in 2012-2013 (figures 2 and 3b). 
{  32% of prevention funding was allocated to 
specific interventions for the three populations at 
highest risk – PWID, SW, MSM (combined as ‘key 
populations’16 in figures 3b and 4) – with a 71% 
increase in 2013.
{  Direct programme funding was relatively low for 
care and treatment, including ART, and decreased 
by 34% in 2013 (figures 2, 3a, 3c and 4).
16  The Tajikistan NASA does not provide a further disaggregation of key 
populations.
{  The costs for programme management and human 
resources were approximately 24.6% and 10.4%, 
respectively, in 2013; combined, this reflects a 7% 
increase in 2013 compared to the previous year 
(figures 2 and 3d).
About 50% of 2012-2013 HIV/AIDS 
spending went into prevention
0% 
20% 
40% 
60% 
80% 
100% 
2012 2013 
HIV-related research 71,541 204,422 
Enabling environment 86,888 223,574 
Social protection 28,632 111,434 
Human resources 1,376,444 1,470,904 
Programme management 3,229,888 3,458,515 
Care and treatment 2,170,198 1,422,283 
Prevention 5,752,333 7,186,761 
TOTAL $12,715,924 $14,077,893
Figure 2: HIV/AIDS funding in Tajikistan 2012 and 2013 by programme component*
*  NASA classification was used. Please see table A2 in Annex for the details about programme components. $ 2,000 allocated for orphans has been added to the 
social care component.
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Prevention 
48.3% 
Care and 
treatment 
13.4% 
Programme 
management 
25.0% 
Human resources 
10.6% 
Others 
2.7% a)
BCC 
9.2% 
Community mobilization 
13.5% 
HTC 
5.8% 
VAP 
3.7% 
Youth 
9.3% 
PLHIV 
0.9% 
Key populations 
31.4% 
PMTCT 
11.1% 
STI 
7.3% 
Blood safety 
6.7% 
Other 
1.3% b)
Provider initiated 
HTC 
12.7% 
ART 
45.3% Lab monitoring 11.3% 
Others 
20.3% 
OI prophylaxis and 
treatment 
10.4% 
c)
Progamme 
management 
65.2% 
Human resources 
27.7% 
Others 
7.1% 
d)
Total budget for 
2012-2013
$ 12,939,094
2012-2013 budget 
for prevention
$ 3,592,481
2012-2013 budget for 
care and treatment
$ 3,592,181
2012-2013 budget for
management and others
$ 10,262,242
Figure 3, a-d: Detailed HIV/AIDS funding allocation in Tajikistan, 2012-2013*, **
*  Source: Republic of Tajikistan. Tajikistan National AIDS Spending Assessment: 2012-2013. Dushanbe, 2014.
**   ‘Key populations’ include PWID, MSM and SW. ‘VAP’ include specific vulnerable groups such as indigenous groups, recruits, truck drivers, prisoners, and 
migrants.
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HOW MUCH IS SPENT? WHERE DOES THE MONEy COME FROM?
Figure 4: HIV/AIDS investments in Tajikistan in 2012-2013 by target population and intervention type*
*  Allocations to key populations in figure 4 are only referring to interventions specific for the respective key population at higher risk for HIV exposure (e.g. 
specific funding for key populations does not include their treatment or testing costs; on the other hand care and treatment includes care and ART for key 
populations).
$0 
$ 500,000 
$ 1,000,000 
$ 1,500,000 
$ 2,000,000 
$ 2,500,000 
$ 3,000,000 
BCC Key populations HTC STI Care and treatment PMTCT 
2012 913,777 1,497,212 387,383 207,496 2,170,198 631,507 
2013 270,702 2,564,282 362,155 733,241 1,422,283 799,744 
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Investments have averted infections 
{  Modelling of the HIV epidemic in Tajikistan 
confirms that if the prevention and treatment 
programmes had not been implemented current 
HIV prevalence and incidence would have been far 
greater, especially among PWID. 
HIV prevalence seems to stabilise or 
declining in some populations
{  Current HIV prevention policies appear to be 
keeping HIV prevalence in decline among PWID 
and stable in most other populations. 
{  The prevalence of HIV among PWID in 2011 (the 
most recent year data were available) was 13.5% 
(23.5% in 2006, 16.3% in 2010); among SW, HIV 
prevalence was 3.7% in 2011 (3.7% in 2006, 4.4% 
in 2010). HIV prevalence among MSM in 2011 was 
1.5%, but the situation in this population remains 
unclear. HIV prevalence in prison inmates was 8.4% 
in 2013 (compared to 8.4% in 2006, 8.5% in 2010).
HIV prevalence is declining among PWID
Late diagnosis is common
{  Surveillance data indicate that testing rates have 
increased in recent years, especially among key 
populations at higher risk.
{  However, the majority (65%) of the estimated 
number of PLHIV remains unaware of their 
infection and ability to transmit the virus to others. 
The majority (65%) of the estimated number 
of PLHIV remains unaware of their infection
{  Late diagnosis also means late initiation of ART, 
which results in poorer clinical outcomes and a 
lower impact through treatment as prevention.
Treatment coverage: depending on 
the way of calculation – but too low 
{  According to RAC, the estimated number of PLHIV 
was 13,841 in 2013 of whom 4,581 (33%) had been 
diagnosed and registered; 1,399 PLHIV (31% of 
those diagnosed) were on ART at the end of 2013 
including an estimated 1,127 with suppressed viral 
load (figure 5).
{  Also in 2013, out of 4,581 PLHIV officially 
registered, 2,516 PLHIV were eligible for ART 
under current national guidelines according to 
RAC. Based on the RAC estimated total number 
of PLHIV (13,841), the model estimates that 5,200 
PLHIV were eligible for ART under the current 
national guidelines17. Estimates for ART coverage, 
therefore, range from 27% (1,399/5,200) to 56% 
(1,399/2,516) based on the current national ART 
guideline, and from 10% (1,399/13,841) to 31% 
(1,399/4,581) based on the estimated and registered 
PLHIV, respectively. While treatment greatly 
improves the quality of life of those who receive it, 
many PLHIV in need of ART are still not receiving 
it. Further, the fraction of people on treatment is 
likely to be too small to have a significant preventive 
effect on HIV transmission at the population level.
17  The national ART guideline that was used in 2013 was written in 2008 and 
approved by the Ministry of Health and Social Protection in 2010.
3.   What are the results of current 
investments?
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10% of the estimated number of PLHIV was 
on ART at the end of 2013
Treatment needs continue to rise 
{  Reported AIDS-related mortality among PLHIV 
declined slightly in 2013 (63 reported deaths 
compared to 113 in 2012)18. As in other countries, 
these figures reflect a considerable underreporting19 
due to general challenges of reporting cause-specific 
mortality, and due to HIV/AIDS specific reporting 
challenges such as loss to follow-up of diagnosed 
PLHIV and the high number of undiagnosed 
PLHIV. 
18  Republic of Tajikistan. Country report on progress in fighting HIV 
epidemic in 2014. Dushanbe:2014.
19  Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends 
in underlying causes of death in people with HIV from 1999 to 2011: a 
multicohort collaboration. The Lancet. 2014; 384(9939):241-8. 
{  The number of PLHIV requiring ART outweighs 
current supply. Demand for treatment, including 
second-line regimens, is expected to increase 
further in the near future.
{  In 2013, WHO released a new integrated 
and consolidated ART guideline20. The 
recommendations are based on evidence that 
treating PLHIV earlier can both keep them healthy 
and lower the amount of virus in the blood, which 
reduces the risk of onward transmission. According 
to the new WHO guideline ART should be initiated 
in adults living with HIV when their CD4 cell count 
falls to 500 cells/mm³ or less regardless of clinical 
status. This will increase the number of PLHIV 
eligible for ART considerably compared to the 
previous WHO guideline and the current national 
guideline in Tajikistan, which recommends ART 
initiation at a CD4 of 350 cells/mm³ or less. 
20  World Health Organisation. Consolidated guidelines on the use 
of antiretroviral drugs for treating and preventing HIV infection. 
Recommendations for a public health approach. Geneva: World Health 
Organisation; 2013.
Figure 5: Treatment cascade for Tajikistan in 2013*
*  Sources: Estimated number of PLHIV, number of PLHIV diagnosed and alive and number of PLHIV on ART – RAC; number of PLHIV on ART with suppressed 
viral load – own estimation.
PLHIV diagnosed & alive on treatment  with suppressed viral load
13,841 4,581 1,399 1,127 
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This chapter summarises key model outputs for the 
following questions: What is the HIV epidemic in 
Tajikistan likely to look like if the response continues 
unchanged? And what will be the return on investment 
by 2020, expressed in new HIV infections and DALYs 
averted? 
Scenario 1: ‘Maintaining the 2013 investment allocations and budget level’ 
HIV incidence is expected to decrease 
slowly
{  The first HIV case in Tajikistan was recorded in 
1991. However, before the early-to-mid 2000s, there 
was little known about HIV in Tajikistan. By the 
end of 2006 there had been a cumulative of 707 
people diagnosed with HIV and officially registered 
which then increased to 5,550 (of which 4,581 were 
still alive) at the end of 2013.
{  For the future projection, the model-estimated 
annual HIV incidence shows a moderate decline 
from approximately 1,450 in 2013 to around 1,150 
in 2,020. 
{  The projected declining incidence is mainly driven 
by key populations at higher risk of HIV exposure; 
in SW incidence is projected to decline by 28%, in 
PWID by 27%, in prison inmates by 27%, in MSM 
by 20%, and in labour migrants by 20%. The model 
also projects spill over effects for lower risk adult 
females and males with incidences declining by 13% 
and 6%, respectively.
HIV transmission mode with little 
changes
{  In 2013, 57.5% of newly diagnosed HIV infections 
were transmitted sexually, 27.3% through injecting 
drug use and 5.4% from mother to child21. Sexual 
transmission and injecting drug use have long 
contributed to HIV transmissions in Tajikistan. 
HIV will continue to be transmitted among PWID 
in Tajikistan but the trend towards a larger share of 
sexual transmissions will progress (figure 6). 
57.5% of newly diagnosed infections in 2013 
were transmitted sexually
21  For 9.8% of newly diagnosed HIV infection in 2013 mode of transmission 
was unknown.
4.   Scenario 1: Maintaining the current 
investment allocations and budget level, 
what will the HIV epidemic look like by 2020?
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Number of PLHIV eligible for ART is 
expected to increase with guideline 
update
{  Current coverage of ART is low even when the 
eligibility is based on the current national guideline 
(see section 3). 
{  Proceeding with the existing investment allocations 
at the current budget level, the estimated number 
of PLHIV is projected to slightly decrease from 
approximately 13,000 in 2013 to 12,000 in 2020 
(figure 7). 
{  The number of PLHIV eligible for ART based on the 
current national ART guideline is expected to slightly 
increase to 5,600, but will increase to 8,200 in 2015 
and only moderately decrease to 7,700 in 2020 if the 
WHO 2013 guideline are adopted in 2015.
Under scenario 1, 5,600 PLHIV will be 
eligible for ART by 2020 and 7,700 if the 
WHO 2013 guideline is adopted
{  Approximately 950 PLHIV will be on first-line ART 
regimen and the number of PLHIV on second-line 
ART regimen will increase to about 400 in 2020.
{  If testing rates are not increased, only 3,300 out of 
the estimated 12,000 PLHIV will know their HIV 
status.
{  Since the total number of PLHIV on ART would 
slightly decrease because of budget constraints and 
the increasing number of second line ART, and 
since the model predicts the number of PLHIV 
to only slightly decrease, ART coverage in 2020 
would remain low between 11% and 41%: 11% of 
the estimated number of PLHIV (1,350/12,000), 
18% of PLHIV eligible for ART according to WHO 
2013 guidelines (1,350/7,700), 24% of PLHIV 
eligible for ART according to the current national 
guidelines (1,350/5,600), 41% of PLHIV registered 
(1,350/3,300). Following the current national 
guidelines (the WHO 2013 guideline) around 4,250 
(6,350) of the PLHIV would be eligible but without 
ART; 1,950 of them would know their status and be 
on a waiting list for ART.
Figure 6:  Model-estimated trend in HIV incidence under Scenario 1  
(‘maintaining the 2013 investment allocations and budget level’)*
* Please see Annexes 1 and 2 for the assumptions underlying the model.
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Return on investment – Scenario 1: 
‘Maintaining the 2013 investment 
allocations and budget level’
{  Compared to the counterfactual scenario of no 
HIV/AIDS programmes at all, ‘maintaining current 
investment allocations and budget ceiling’ would 
avert around 3,100 new HIV infections and 5,000 
DALYs by the end of 2020 at a total programme 
cost of $ 98.5 million (not accounting for inflation).
Figure 7:  Estimated numbers of PLHIV, of PLHIV eligible for ART and of PLHIV on ART  
(Scenario 1 – ‘maintaining the 2013 investment allocations and budget level’)
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 SCENARIO 1: MAINTAINING THE CURRENT INVESTMENT ALLOCATIONS 
AND BUDGET LEVEL, WHAT WILL THE HIV EPIDEMIC LOOK LIKE By 2020?
5.   Scenario 2: What can be improved by 
optimising efficiencies under the current 
budget envelope?
This chapter summarises key model outputs for the 
following questions: Can more be achieved with the 
same amount of resources, how can this be achieved 
and what would be the return on investment by 2020? 
Scenario 2 – ‘optimising the investment allocations at the 2013 budget level’ 
More value for money through 
technical efficiency
{  With the need to achieve more, it is important to 
consider how unit costs can be reduced. If unit 
costs are reduced, more can be done with the same 
resources. 
{  Overall management and administration costs 
appear to be high compared with direct programme 
costs and other countries in the region. 
{  It is understood that a substantial part of the 
HR costs are used for salary top-ups for service 
providers using external funding sources. It is not 
clear how this will be sustained in the future.
Programme management and human 
resources costs are higher than in other 
countries of the region
{  Room for additional technical efficiency may exist 
when considering the most efficient models of 
service delivery and removing existing structural 
barriers that limit the effectiveness and efficiency of 
current service delivery.
{  On the other hand, the recent WTO accession is 
expected to result in higher procurement costs for 
some ARVs still under patent. In addition, some 
savings will be needed to invest in improved QA/QI 
processes of programme implementation, among 
them adequate management of healthcare waste 
generated by programme interventions22. 
More value for money through 
allocative efficiency
Background for allocative efficiency
{  The resource allocation in Tajikistan must take into 
account the disease burden, the distribution among 
sub-populations and the potential for impact. There 
is an important opportunity to further improve 
the resource allocation to programme components 
and sub-populations in such a way that the greatest 
impact can be achieved.
{  Allocative efficiency can be considered the 
allocation of resources in the best combination 
across various programme components that leads 
to optimal outcomes and impact within a defined 
budget envelope. As such, modelling allocative 
efficiency is not sufficient to determine the overall 
budget envelope needed to achieve defined targets, 
In addition, allocative efficiency is assessed here 
22  Kühling JG. Rapid assessment: Healthcare waste component of Global 
Fund HIV, TB and Malaria projects in Tajikistan. Istanbul: United Nations 
Development Programme Istanbul Regional Centre for Europe and Central 
Asia; 2014.
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from the perspective of an individual disease 
programme, and not across the health sector or 
beyond. 
Allocative efficiency is considered here as 
an optimal allocation mix within a defined 
budget envelope
Methods for allocative efficiency
{  A formal mathematical optimisation procedure 
surrounded an epidemiological transmission model 
to calculate the allocation of resources across HIV 
programme components which is likely to result 
in the least number of new HIV infections and 
DALYs over the 2014-2020 period; it uses the 
2013 investment allocations as a starting point 
and keeps the budget constant on 2013 amounts 
(see table A2 in Annex for more details). The 
model was informed by available epidemiological, 
behavioural and clinical data, as well as likely 
programme outputs and other outcomes associated 
with possible funding combinations over all 
programmes.
{  For the model, two alternative options were 
considered: 
Option A: Improving allocative efficiency for 
the prevention and the care and treatment 
programme components, comprising 
about 60% of the total budget in 2013; the 
programme management and HR components 
were left constant.
Option B: Improving allocative efficiency for 
the prevention and the care and treatment 
programme components, but reducing 
allocations for programme management and 
HR by 20% (which equals approximately $ 
1 million) and using the savings to further 
improve the allocative efficiency for the 
prevention and the care and treatment 
components.
{  For both options, prevention of HIV transmission 
aimed for PLHIV, blood safety, and ‘other 
prevention’ (prevention of the HIV transmission at 
the workplace, post-exposure prophylaxis), provider 
initiated HIV testing, and ‘other’ programme 
components (orphans and vulnerable children, 
social protection, enabling environment, and HIV-
related research) were kept constant 
{  For option B, savings in programme management / 
HR were partially used to continue services which 
are essential components of the national HIV 
programme but were set to zero or substantially 
reduced under option A due to their assumed 
lower effectiveness in the overall context of service 
rationalization.
{  The most cost-effective interventions are those 
that have proven effectiveness in reducing risk 
behaviours and/or biological transmissibility, or 
improving survival and health, and are targeted 
to groups of people at greatest risk of acquiring 
or transmitting HIV. The optimisation procedure 
automatically factors these considerations into the 
calculation of ideal allocations taking into account 
costs and the level of effectiveness to meet a given 
objective.
{  There will be different optimal allocations for 
different objectives. For example, objectives could 
include: minimising the number of new infections 
with current resources; minimising the number of 
deaths with current resources; or minimising the 
amount of money required to achieve a certain 
percentage decline in new infections or to meet 
the targets of the national strategic plan, such as 
providing universal coverage for prevention and 
treatment services. 
{  Here, the objective reflected the UNAIDS ‘Getting 
to Zero’23 vision by minimising both DALYs 
(accounting for disease progression and death) 
and new HIV infections by 2020 with current 
(2013) resources. Each additional infection 
was considered equivalent to 20 DALYs, a value 
which takes into account both DALYs outside the 
window of the intervention period as well as the 
effect of subsequent infections. While the model 
is optimised for the period until 2030, the outputs 
23  The UNAIDS ‘Getting to zero’ strategy for 2011-2015 has three 
components: to get to zero new infections, zero AIDS-related deaths and 
zero discrimination. 
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EFFICIENCIES UNDER THE CURRENT BUDGET ENVELOPE?
are discussed in this chapter for the short- and 
mid-term period until 2020 to focus on the current 
programming needs under the GF new funding 
model in Tajikistan.
Allocative efficiency is considered here 
as an optimal allocation mix to reach the 
objectives of minimizing new HIV infections 
and DALYs
{  The model takes into account the dual impact 
of ART: ‘treatment as prevention’24. It could be 
assumed that treatment reduces transmission 
risk by as much as 96% based on the HPTN-
052 clinical trial setting25, but this may be an 
overestimation. In an observational cohort study 
of serodiscordant couples in China it was shown 
that HIV transmission was reduced by only 26% 
due to ART26. Based on a large review of literature 
we conducted across many settings, adherence 
to ART was estimated as 75% for the model; at 
92-96% efficacy for full adherence, this weights to 
approximately 70% efficacy of ART in reducing 
infectiousness when accounting for observed 
adherence patterns. Therefore, we assumed that 
ART reduces transmission by 70%27. 
The model assumes that ART reduces the 
probability of HIV transmission by 70%
24  World Health Organisation. Antiretroviral treatment as prevention (TASP) 
of HIV and TB. Geneva: World Health Organisation; 2012.
25  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, 
Kumarasamy N, et al. Prevention of HIV-1 infection with early 
antiretroviral therapy. N Engl J Med. 2011;365:493–505.
26  Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, et al. Antiretroviral therapy to 
prevent HIV transmission in serodiscordant couples in China (2003-11): a 
national observational cohort study. Lancet. 2013;382:1195–203.
27  Regional studies on the impact of ART on preventing HIV transmissions 
in key populations at higher risk are not available; such studies would be 
useful to improve investment decisions.
Modelling results for allocative efficiency
{  Current resource allocations strike a compromise 
between an optimal HIV incidence-reduction 
strategy and an optimal DALY-reduction strategy. 
{  It was identified that overall the current (2013) 
budget envelope is insufficient to scale up all 
essential and effective standard interventions to 
universal coverage. Therefore, the results for an 
optimised allocative efficiency under the current 
budget ceiling (i.e. for the currently underfunded 
programme) must be interpreted with caution 
in the context of service rationalisation. This 
is especially true when considering competing 
effectiveness of essential key interventions aimed at 
reducing infections, disease burden and death.
The current budget is insufficient to scale 
up essential HIV interventions to universal 
coverage, even under optimized efficiencies
{  With these constraints in mind, the model suggests 
an optimised resource allocation under the 2013 
budget constraints by shifting resources from BCC, 
community mobilisation, prevention for ‘vulnerable 
and accessible’ populations and youth towards key 
populations at higher risk for HIV infection, and 
for option A from HTC towards treatment given 
the low treatment rates which mean, under the 
model assumptions, relative limited benefits from 
diagnosing additional people (figure 8, table 1).
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Figure 8, a-c:  Comparison of budget allocations under the current (2013) budget envelope; a) current (2013) 
allocations, b) optimised allocations option A, and c) optimised allocations option B*,**
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*  See narrative for further explanation of option A and B.
**   Based on NASA clasification, ‘VAP’ category includes includes specific vulnerable groups such as indigenous groups, recruits, truck drivers, prisoners, and 
migrants.
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Table 1:  Comparison of budget allocations under the current (2013) budget envelope: current (2013) 
allocation mix, optimised allocation option A and optimised allocation option B*,**
Budget allocation in $
a) current 
(2013) 
allocation
b) optimised 
allocation, 
option A 
c) optimized 
allocation, 
option B
HIV spending TOTAL 14,077,893 14,077,893 14,077,893
Prevention SUBTOTAL 7,186,761 6,682,225 7,458,762
Prevention – blood safety, PLHIV, other 555,040 555,040 555,040
Communication for social and behaviour change (BCC) 270,702 0 79,331
Community mobilization 886,404 0 259,830
HIV testing and counselling (HTC) 362,155 307,433 362,155
Programmatic interventions for vulnerable and accessible population 295,655 0 86,653
Prevention – youth in school 362,977 0 106,390
Prevention – youth out-of-school 356,561 0 104,480
Prevention programmes for key target populations (PWID, SWs, MSM) 2,564,282 4,162,560 4,162,560
Prevention, diagnosis and treatment of STI for general population 733,241 670,850 755,981
PMTCT not disaggregated by intervention 799,744 986,342 986,342
Care and Treatment SUBTOTAL 1,422,283 1,926,819 2,136,166
Provider initiated testing and counselling 277,130 277,130 277,130
Care and treatment – ART, OI prevention, lab. monitoring, other 1,145,153 1,649,689 1,859,036
Programme management and Human resources SUBTOTAL 4,929,419 4,929,419 3,943,535
Others – OVC, social protection, enabling environment, HIV-
related research SUBTOTAL
539,430 539,430 539,430
*   Allocations to key populations in table 1 are only referring to interventions specific for the respective key population at higher risk for HIV infection (e.g. 
specific funding for key populations does not include their treatment or testing costs; on the other hand care and treatment includes care and ART for key 
populations).
**   See narrative for further explanation of option A and B.
Improved impact – but still 
insufficient service coverage
{  Modelling allocative efficiency (figure 9) results by 
2020 in28:
 P  an estimated 11,500 PLHIV;
 P  an estimated 6,000 PLHIV eligible for ART 
in 2020 based on the current national ART 
28  Outcomes are shown only for the optimized budget allocation with 20% 
reduction of programme management and HR allocations (option B).
guideline, and 7,900 if the WHO 2013 guideline 
are adopted in 2015;
 P  around 1,800 PLHIV will be on first-line ART 
regimen and 500 PLHIV will be on second-line 
regimen in 2020;
 P  an estimated ART coverage of 20% to 96%: 
20% among estimated number of PLHIV 
(2,300/11,500); 29% among PLHIV eligible 
for ART according to WHO 2013 guidelines 
(2,300/7,900); 38% among PLHIV eligible 
for ART according to the current national 
guidelines (2,300/6,000); and 96% registered 
PLHIV (2,300/2,400).
Modelling an optiMised investMent approach for tajikistan26
Figure 9:  Estimated numbers of PLHIV, of PLHIV eligible for ART and of PLHIV on ART  
(Scenario 2 – ‘optimising the investment allocations at the 2013 budget level’ using option B)*
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* See narrative for further explanation of option B.
Return on investment – Scenario 
2: ‘Optimising the investment 
allocations under 2013 budget level’ 
{  Compared to the counterfactual scenario of no 
HIV/AIDS programmes at all, ‘optimising the 
investment allocations under the current budget 
level’ would avert around 4,400 (4,200)29 new HIV 
infections and 15,600 (12,500)30 DALYs by the end 
of 2020 at a total programme cost of $ 98.5 million. 
29 Scenario 2 option B (scenario 2 option A).
30 Scenario 2 option B (scenario 2 option A).
SuStainable Financing oF national HiV ReSponSeS 27
 SCENARIO 2: WHAT CAN BE IMPROVED By OPTIMISING 
EFFICIENCIES UNDER THE CURRENT BUDGET ENVELOPE?
This chapter summarizes key model outputs for the 
questions: Using optimized efficiencies, how much 
would it take to achieve universal coverage for the key 
prevention and treatment services, and what would 
then be the return on investment by 2020? 
Scenario 3 – ‘scaling up to universal coverage by 2020’ 
Shortfalls of the current and 
optimised investment case under the 
current budget ceiling
{  The modelling results of scenario 1 and 2 clearly 
demonstrate the limitations of the current budget 
level: too many PLHIV will remain undiagnosed 
and without essential services, even under 
optimised allocative efficiency and reduced 
programme management and HR costs; the impact 
on HIV incidence and DALYs remains limited.
Keeping the current budget envelope means: 
too many PLHIV will remain undiagnosed 
and without essential services
{  ‘Doing more and better with less’ is an important 
call for continuous quality improvement and 
efficiency gains, but there is clearly a threshold 
below which a budget simply becomes insufficient 
to fully meet the objectives.
{  The current epidemic indicators, service coverage 
and the modelling forecast show that overall the 
HIV response is underfunded in Tajikistan in order 
to meet its objectives of ‘Getting to Zero’ and of 
fulfilling the commitments for universal coverage of 
essential HIV services.
Modelling the scale-up to universal 
coverage of essential HIV services
Background on universal coverage
{  Commitment to universal coverage of HIV 
service in Europe and Central Asia is reflected in a 
number of declarations, including the 2004 ‘Dublin 
Declaration on Partnership to Fight HIV/AIDS 
in Europe and Central Asia’31, the 2004 ‘Vilnius 
Declaration on Measures to Strengthen Responses 
to HIV/AIDS in the European Union and in 
Neighbouring Countries’32, and the 2007 ‘Bremen 
Declaration on Responsibility and Partnership – 
Together Against HIV/AIDS’33. Tajikistan is one 
31  Dublin Declaration on Partnership to fight HIV/AIDS in Europe and 
Central Asia. Breaking the Barriers – Partnership to fight HIV/AIDS in 
Europe and Central Asia Conference; 2004, Feb 23-24; Dublin, Ireland.
32  Vilnius Declaration on Measures to Strengthen Responses to HIV/AIDS 
in the European Union and in Neighbouring Countries. Europe and HIV/
AIDS – New Challenges, New Opportunities Conference; 2004, Sept 17; 
Vilnius, Lithuania.
33  Bremen Declaration on Responsibility and Partnership – Together Against 
HIV/AIDS. ‘Responsibility and Partnership -Together Against HIV/AIDS’ 
Conference; 2007, Mar 12-13; Bremen, Germany.
6.   Scenario 3: Fulfilling the commitments 
for people in need – the rights-based 
investment case
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of 55 countries included in the monitoring of 
progress against the commitments of the Dublin 
declaration34. 
{  In accordance with the MDG6, the main goal of the 
National AIDS Programme of Tajikistan is to halt 
and begin to reverse the spread of HIV through 
universal access to prevention, treatment, care and 
support35; this is reconfirmed in the new National 
HIV/AIDS response strategy (2015-2017) of the 
Republic of Tajikistan36.
{  Universal health coverage is being considered as 
one of the targets under the proposed Sustainable 
Development Goal for health and it plays a key 
role in the positioning of health in the post-2015 
development agenda37.
Without universal coverage of essential HIV 
services, ending the epidemic of AIDS by 
2030 will be unrealistic
{  Without universal coverage of key prevention 
and treatment services, the target of ending 
the epidemic of HIV/AIDS by 2030 as recently 
proposed by the Open Working Group38 will be 
unrealistic.
34  European Centre for Disease Prevention and Control. Thematic report: 
Combined reporting – Monitoring implementation of the Dublin 
Declaration on Partnership to Fight HIV/AIDS in Europe and Central 
Asia: 2012 progress. Stockholm: European Centre for Disease Prevention 
and Control; 2013.
35  The Government of Tajikistan. Programme on the response to the epidemic 
of HIV/AIDS in the Republic of Tajikistan for the period 2011-2015. 
Dushanbe: the Government; 2010.
36  Republic of Tajikistan. National HIV/AIDS response strategy (2015-2017) 
in Republic of Tajikistan. Dushanbe: National Coordination Committee to 
Combat HIV/AIDS, Tuberculosis and Malaria in the Republic of Tajikistan; 
2014.
37  World Health Organisation. Positioning Health in the Post-2015 
Development Agenda – WHO Discussion Paper; 2012. 
38  Open Working Group of the General Assembly on Sustainable 
Development Goals. Introduction and proposed goals and targets on 
sustainable development for the post 2015 agenda. New York: Opening 
Working Group; 2014.
Methods for modelling universal coverage  
of essential HIV prevention, treatment and  
care services
{  Using the same model structure as described in the 
previous chapter and detailed in the Annex, the 
objective of a rights-based investment approach 
is to reach universal coverage of essential HIV 
prevention services and ART by 2020.
{  Starting at the current (2013) estimated service 
coverage for HTC, ART, PMTCT and special 
interventions for key populations, the model 
assumed an approximately linear increase over time 
to reach universal coverage for the key prevention 
and ART services by 2020.
{  For ART services, the model investigated 
alternatively the following three options to 
determine universal coverage: 
Option A: 95 percent of diagnosed PLHIV and 
eligible for ART under the current national 
ART guideline; 
Option B: 95 percent of diagnosed PLHIV and 
eligible for ART under the WHO 2013 guideline;
Option C: 95 percent of all diagnosed PLHIV 
(‘test and treat’ concept39). 
{  For PMTCT, the objective of the modelling was to 
achieve 95% coverage; for harm reduction specific 
to PWID and special preventive service for other 
key populations 80% coverage of estimated need 
was used. For HTC the objective was that 80% of 
key populations at higher risk would know their 
status. 
39  Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV 
elimination by ‘test and treat’ in hyperendemic settings. AIDS. 
2010;24(5):729-35.
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Modelling results for a rights-based investment 
case approach 
{  To achieve universal treatment access under 
scenario 3 option C (‘test and treat’) the number of 
PLHIV on ART would need to reach around 9,700, 
for option B (WHO 2013 guideline) approximately 
9,000 and for option A (current national guideline) 
about 8,200 by 2020. This reflects a 6- to 7-fold 
increase to 2013 ART figures. 
{  The number of people tested during the last 12 
months will be 9% higher in 2020 than in 2013.
{  Since the coverage rate for PMTCT is already high, 
it would see only a modest increase by 2020.
{  NSP/OST coverage of PWID will increase 
substantially to reach at least 20,000 PWID by 2020.
With a rights-based investment approach the 
number of PLHIV on ART would increase 
6- to 7-fold
Return on investment –  
Scenario 3: ‘Scaling up to universal 
coverage by 2020‘
{  Under the assumption of the universal coverage 
for key preventive and treatment interventions, 
the epidemic impact would depend on the applied 
criteria for ART eligibility, as shown in table 2. 
Table 2:  Projected estimated epidemiological impact and programme costs* (point estimates) using three 
options** for ART eligibility criteria for Scenario 3: ‘Scaling up to universal coverage by 2020’
Universal ART coverage
By 2020 Option A Option B Option C
Estimated PLHIV 13,670 13,660 12,700
Estimated new HIV infections averted*** 7,000 7,150 8,360
Estimated DALYs averted*** 95,400 100,000 101,700
Total programme costs 2014-2020 $ 123.3 million $ 126.6 million $ 129.0 million
*  Not accounting for inflation.
**  See narrative for further explanation of option A, B and C.
***  Compared to the counterfactual scenario of no HIV/AIDS programmes at all.
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This chapter summarises and compares key model 
outputs for the short- and long-term impact of scenario 
1 (‘maintaining the 2013 investment allocations and 
budget level’), scenario 2 (‘optimising the investment 
allocations at the 2013 budget level’) and scenario 3 
(‘scaling up to universal coverage’).
The rights-based investment 
approach – highest impact on HIV 
infections and DALys in the short-term
{  In the previous chapters, model predictions showed 
the highest impact for scenario 3 ‘scaling up to 
universal coverage’ in terms of averting new HIV 
infections and DALYs by 2020; this is also the only 
scenario fulfilling international commitments made 
and key goals of the National AIDS Programme. 
Comparisons of projected impact and costs are 
summarized in table 3.
The rights-based investment 
approach – highest impact on HIV 
infections and DALys also in the long-
term
{  The long-term impact of scenario 3 until 2030 
is even more impressive; figure 10 shows the 
comparison of all scenarios.
{  Under scenario 3, the estimated number of PLHIV 
would be around 13,500 by 2030 using current 
national treatment guidelines, approximately 13,700 
using the WHO 2013 treatment guideline, and 
about 12,300 using the ‘test and treat’ approach. 
This compares to an estimated 9,000 PLHIV for 
scenario 240 and 10,700 for scenario 1 (figure 
10a). Differences can be explained by long-term 
dynamics of differences in averted HIV infections 
and averted HIV-related deaths.
{  An estimated cumulative total of around 29,000 
new HIV infections would be averted between 2014 
40  Using the optimized budget allocation with 20% reduction of programme 
management and HR allocations (option B).
7.   Rights-based investment today – the 
highest impact now and in the future
Table 3:  Point estimates of cumulative new HIV infections averted, cumulative DALYs averted and total 
programme costs under the three different scenarios (2014-2020)
Scenario 1 Scenario 2 Scenario 3
Option A*
Scenario 3
Option B*
Scenario 3
Option C*
New HIV infections averted 3,100 4,400 7,000 7,150 8,360
DALYs averted 5,100 15,600 95,400 100,000 101,700
Total programme costs $ 98.5 million $ 98.5 million $ 123.3 million $ 126.6 million $ 129.0 million
*  Option A: 95% of diagnosed AND eligible PLHIV by 2020, current national guideline; option B: 95% of diagnosed AND eligible PLHIV by 2020, WHO 2013 
guideline; option C: 95% of all diagnosed PLHIV by 2020 (‘test and treat’).
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and 2030 under scenario 3 using the ‘test and treat’ 
approach (around 27,000 using the WHO 2013 
guideline, around 26,500 using current national 
guidelines). Scenario 2 and 1 achieve significantly 
lower numbers of averted new HIV infections, 
approximately 20,000 and 16,000 respectively 
(figure 10b).
{  Between 2014 and 2030 nearly 323,000 DALYs 
would be averted under scenario 3 using the ‘test 
and treat’ approach (314,000 using the WHO 
2013 guideline, 302,000 using current national 
guidelines). Scenario 2 (119,000) and scenario 1 
(78,000) avert less than half the number of DALYs 
(figure 10c).
Figure 10 a-c:  Long term comparisons (2013-2030) of the epidemiological impact of scenario 1, 2 and 3;  
a) estimated number of PLHIV, b) estimated annual number of new HIV infections averted, and 
c) estimated annual number of DALYs averted*,**
*   For scenario 2 option B was used. For more details see chapter 5.
**   For figures 10b and 10c these analysed figures reflect the 12 month period before the each year.
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All mathematical models have their limitations and 
results should therefore be interpreted with the 
necessary caution. 
{  All model forecasts are subject to uncertainty. 
Therefore, point-estimates indicate trends rather 
than exact figures. 
{  The model calibration depends as much on the 
quality of input data as on the quality of the model 
itself. The country and study teams including the 
RAC paid much attention to assure data quality. 
However, there is room for improvement in further 
studies, both in terms of data quality and model 
structures. 
{  The best model calibration will rarely achieve an 
exact match of historical data, but mirror as closely 
as possible the key trends of them.
{  Modelling the optimization of allocative efficiencies 
depends critically on the availability of evidence-
based parameter estimates of the effectiveness and 
cost-efficiency of individual interventions.
{  Particularly interventions related to the so-called 
critical enablers41 such as interventions against 
punitive laws and discrimination, community 
mobilization, but also interventions related to 
health systems strengthening often lack ‘hard’ 
effectiveness data in relation to the key impact 
indicators such as new HIV infections or DALYs 
averted. Under resource constraints like in scenario 
2, the model will therefore suggest to reduce or 
even stop such interventions which requires to set 
model restrictions like fixing allocations at certain 
minimum amounts. 
{  Even for clinical interventions, the effectiveness 
in general but particularly in a specific country 
or population setting is less clear than commonly 
41  UNDP, UNAIDS. Understanding and acting on critical enablers and 
development synergies for strategic investments. New York: UNDP; 2012.
thought. Assumptions need therefore to be made 
in a transparent way so that they can be reviewed. 
One of the critical assumptions – the effectiveness 
of ART on HIV prevention – has been presented in 
detail, others are referred to in the Annex.
{  The model operates largely with current unit costs. 
Although the effect of increases or decreases of unit 
costs can be estimated with the model, the model 
itself cannot suggest what unit cost is adequate to 
achieve a defined standard of service quality or 
even what the defined standard should be. There is 
very little information about service quality and its 
contextual effect on impact available for Tajikistan 
or for the region. This is an area which deserves 
much greater attention particularly in times in 
which funding mechanisms such as the new 
funding model of the GF structurally incentivise 
reduction of unit costs without having adequate 
quality monitoring measures in place.
{  Finally, no allocative efficiency optimization within 
a budget framework that is not sufficient to meet 
the needs for essential health services can replace 
the rights for basic health services. On the other 
hand, waste of resources under conditions of global 
resource constraints, low service coverage and 
inequities in service access make the fulfilment 
of these basic rights even more difficult. The key 
message of this document is therefore: With a 
moderate increase of the investment volume until 
2020 combined with an optimized investment 
allocation the national HIV response in Tajikistan 
can be brought on a trajectory which fulfils the 
basic rights to access to essential HIV services for 
those in need and makes ending the epidemic threat 
of HIV/AIDS in Tajikistan a realistic goal if an 
environment without stigma and discrimination is 
provided so that services available will be accepted 
and used by the affected communities.
8.  Remarks
SuStainable Financing oF national HiV ReSponSeS 33
Susceptible
Undiagnosed
CD4>500
Undiagnosed
300<CD4<500
Undiagnosed
200<CD4<350
Undiagnosed
CD4<200
Diagnosed
CD4>500
Diagnosed
300<CD4<500
Diagnosed
200<CD4<350
Diagnosed
CD4<200
1st-line treatment
CD4>500
1st-line treatment
300<CD4<500
1st-line treatment
200<CD4<350
1st-line treatment
CD4<200
Infection Death Treatment eect Diagnosis rate Treatment rate Treatment failure rateDisease progression
Treatment failure
CD4>500
Treatment failure
300<CD4<500
Treatment failure
200<CD4<350
Treatment failure
CD4<200
2nd-line treatment
CD4>500
2nd-line treatment
300<CD4<500
2nd-line treatment
200<CD4<350
2nd-line treatment
CD4<200
Annex 1. Model description
Overview of analytical methods
To assess HIV epidemic trends, resource needs, the 
cost-effectiveness of past programmes, and the impact 
of potential future programmes, we developed a 
detailed mathematical model of HIV transmission 
and disease progression, called the Projection and 
Evaluation Tool (Prevtool).
Prevtool is a flexible population-based HIV model. The 
basic disease progression implemented in the model is 
shown in figure A1. This is the only aspect of the model 
structure that is fixed, and specifies it as being an HIV 
model instead of a universal epidemic model.
In contrast to most other HIV models, the population 
groups used in Prevtool are not fixed. Instead, up to 
14 user-defined population groups may be used. A 
typical example for a concentrated HIV epidemic, 
such as used in Tajikistan, is shown in figure A2. Here, 
seven population groups are used, including low-risk 
(‘general’) males and females, SWs and their clients, 
male and female PWID, and MSM. 
Data are entered into Prevtool by means of an Excel 
spreadsheet, as shown in figure A3. Data entry is 
flexible, allowing everything from a separate data point 
for every population for each year, or a single data 
point for all populations over the entire time period. 
Annex
Figure A1: Schematic diagram of model structure*
*  Each compartment represents a single population group with the specified health state, while each arrow represents the movement of individuals between health 
states. All compartments except for ‘Susceptible’ represent individuals living with HIV. ‘Death’ includes all causes of death.
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The model uses a coupled system of ordinary 
differential equations to track the movement of people 
between health states. The overall population is 
partitioned in two ways: by group and by health state. 
Individuals are assigned to a given population based 
on their dominant risk; however, to capture important 
cross-modal types of transmission (e.g., SW becoming 
infected via injecting drug use), relevant behavioural 
parameters can be set to small but nonzero values (e.g., 
male PWID occasionally engage in commercial sex; 
MSM occasionally inject drugs).
The rate at which uninfected individuals in each 
population group become infected is determined by the 
force-of-infection for that population. This depends on 
the number of risk events an individual is exposed to 
in a given period of time and the infection probability 
of each event. Sexual transmission risk depends on 
the number of people in each HIV-infected stage (that 
is, the prevalence of infection in the population of 
partners), the average number of casual, regular, and 
commercial homosexual and heterosexual partnerships 
per person, the average frequency of sexual acts per 
Figure A2:  Population groups and interactions in 
Prevtool, example
Figure A3: Example of data entry spreadsheet for a concentrated epidemic (in this case, Tajikistan)*
* In addition to best-estimate data, upper and lower bounds are provided (or estimated) for each point.
For layout: please replace this figure 
with the excel sheet ‘A3’ from the dataset 
package.
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partnership, the proportion of these acts in which 
condoms are used, the efficacy of condoms, the extent 
of male circumcision, and the prevalence levels of STIs 
(which increase transmission probability) and HIV.
The stage of infection (chronic, AIDS-related illness/
late stage, or on treatment) for the HIV-positive partner 
in a serodiscordant couple also influences transmission 
risk due to different levels of infectiousness in each 
infection stage. Intravenous transmission risk depends 
on the number of injecting partners per person per 
year, frequency of injecting per year, frequency of 
sharing injecting equipment and %age of shared 
syringes that are cleaned before re-use and the efficacy 
of cleaning. 
Mathematically, the force-of-infection is given by:
λ = 1−(1−β)n
where λ is the force-of-infection, β is the transmission 
probability of each event, and n is the effective number 
of at-risk events (thus n gives the average number 
interaction events with infected people where HIV 
transmission may occur). The value of the transmission 
probability β is based n average viral load of people in 
different stages of infection and transmissibility differs 
by mode of transmission (intravenous drug injection, 
heterosexual intercourse, and homosexual intercourse), 
and may be modified by behavioural interventions (for 
example, condom use or circumcision). The number 
of events n not only incorporates the total number 
of events, but also other factors that moderate the 
possibility that these events are capable of transmitting 
infection, such as condom use or circumcision. There is 
one force-of-infection term for each type of interaction 
(for example, casual sexual relationships between low-
risk males and indirect female sex workers), and the 
force-of-infection for a given population will be the 
sum of overall interaction types.
In addition to the force-of-infection rate, in which 
individuals move from uninfected to infected states, 
there are seven other means by which individuals may 
move between health states. First, individuals may die, 
either due to the background death rate (which affects 
all populations equally), due to injecting behaviour, 
or due to HIV/AIDS (which depends on CD4 count). 
Second, in the absence of intervention, individuals 
progress from higher to lower CD4 counts. Third, 
individuals can move from undiagnosed to diagnosed 
states based on their HIV testing rate, which is a 
function of CD4 count (for example, people with AIDS 
symptoms have a higher testing rate) and population 
type (for example, SW usually get tested more 
frequently than low-risk males). Fourth, diagnosed 
individuals may move onto treatment, at a rate which is 
dependent on CD4 count. Fifth, individuals may move 
from treatment to treatment failure, and sixth, from 
treatment failure onto second-line treatment. Finally, 
while on successful first- or second-line treatment, 
individuals may progress from lower to higher CD4 
count and they will have reduced infectiousness.
In total, the model can accommodate up to 294 
compartments (14 populations each with 21 health 
states), and the change in the number of people in 
each compartment is determined by the sum over 
the relevant rates described above multiplied by 
the compartments on which they act. For example, 
the number of individuals in the compartment 
corresponding to undiagnosed female SW with a CD4 
count between 200 and 350 cells/µL changes according 
to the following equation:
where 350 −500 is the current population size of people 
with undiagnosed HIV and with a CD4 count between 
350 and 500 cells/μL, 200 −350   is the population size 
of the compartment with lower CD4 count (200-350 
cells/μL), τ is the disease progression rate for the given 
CD4 count, μ is the death rate, and η is the HIV testing 
rate. (Note: this example does not consider movement 
between populations, such as female SW returning to 
the low-risk female population and vice versa.) Each 
compartment (figure A1, boxes) corresponds to a 
single differential equation in the model, and each rate 
(figure A1, arrows) corresponds to a single term in that 
equation.
Most of the parameters in the model are related to 
calculating the force-of-infection; a list of model 
parameters is provided in table A1. Empirical estimates 
for model parameter values can be interpreted in 
Bayesian terms as prior distributions. The model must 
then be calibrated, which is the process of finding 
200 −350 = 350 −500 350 −500 − 200 −350 ( 200 −350 + 200 −350 + 350 −500 )
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posterior distributions of the model parameter values 
such that the model generates accurate prevalence 
estimates. Given the challenges inherent in quantifying 
all known constraints on the epidemic, initial 
calibration is performed manually, with oversight 
by and collaboration with in-country stakeholders 
where possible. This prior distribution is then used in 
a Monte Carlo Markov chain algorithm, which uses 
both epidemiological and behavioural data to calculate 
the log-likelihood for a given set of model parameters. 
The distribution of parameter values produced by the 
Monte Carlo Markov chain is the posterior, which 
is then used for all epidemiological and economic 
analyses. An example calibration is shown in figure A4.
Table A1: Input parameters of the model
Biological parameters Behavioural parameters Epidemiological parameters
Population parameters Background death rate Population sizes (TP)
HIV-related parameters Sexual HIV transmissibilities* (H)
STI-related transmissibility 
increase*
Condom efficacy*
Circumcision efficacy*
HIV health state progression 
rates (H)
HIV-related death rates (H)
Number of sexual partners* 
(TPS)
Number of acts per partner* (S)
Condom usage probability* (TP)
Circumcision probability* (T)
HIV prevalence (TP)
STI prevalence (TP)
MTCT parameters Mother-to-child transmission 
probability
Birth rate
PMTCT access rate (T)
Injection-related parameters Injecting HIV transmissibility*
Syringe cleaning efficacy*
Drug-related death rate
Number of injections* (T)
Syringe sharing probability* (T)
Syringe cleaning probability*
Methadone treatment 
probability (T)
Treatment parameters ART efficacy*
ART failure rates
HIV testing rates (TPH) Number of people on ART (T)
Key: T = parameter value changes over time; P = parameter value depends on population group; H = parameter depends on health state; S = parameter depends on 
sexual partnership type; * = parameter is used to calculate the force-of-infection.
Figure A4: Calibration of Prevtool to Tajikistan epidemic data*
*  Dots show data; lines show model outputs; shaded regions are 95% confidence intervals.
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Relationships between spending and 
risk behaviours
In our analysis, we use a logistic/sigmoid function 
to describe the relationships between a behavioural 
parameter affected by a HIV prevention programme 
and the level of spending on that programme. Using 
this function with assumed uncertainties bounds, 
we obtain logistic curve fits to available datasets 
for overall programme spending and associated 
behaviours. Indirect costs have no direct impact on 
HIV transmission parameters; but changes to HIV 
programmes may affect these costs to supply additional 
condoms, clean syringes, and methadone, for 
example. Using these relationships, any change in HIV 
programme funding directly affects risk behaviours 
and changes to the HIV epidemic; an example of 
this is demonstrated in figure A5. The fitted logistic 
relationships will represent the change in behaviours 
with spending.
Figure A5: Example of the relationship between spending on SW/client programmes and the HIV epidemic*
* Numerical values are for illustrative purposes only.
Counterfactual scenarios
Prevtool calculates the cost-effectiveness of past HIV 
programmes by comparing the expected number of 
new infections and HIV/AIDS related deaths according 
to current and past conditions with the estimated 
numbers under counterfactual scenarios in the absence 
of funding for specific programmes. 
We simulate counterfactual scenarios using 
Prevtool based on the assumed effect of the removal 
or enhancement of specific programmes. The 
calibrated simulations with the programmes in place 
represent the baseline scenario. For each prioritised 
population, we develop counterfactual scenarios for 
the behavioural parameters affected by prevention 
programmes prioritising that population — with the 
parameters for the other populations remaining at 
their values obtained through the calibration process. 
Specific counterfactual scenarios used depend on 
the implementation and characteristics of HIV 
prevention programmes and the data available. We fit 
a logistic function to behavioural parameters affected 
by prevention programmes; figure A6 shows some 
example logistic functions for Tajikistan.
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Cost-effectiveness calculations for 
past evaluations 
For each counterfactual scenario, we measure 
the health benefits of a specific HIV intervention 
programme in terms of HIV infections averted as 
well as life years and DALYs saved compared to the 
baseline scenario. We calculate incremental cost-
effectiveness ratios to estimate the cost-effectiveness 
of each programme. These are calculated based on the 
counterfactual scenarios and comparing the spending 
of each programme (discounted annually), as well 
as estimated annual healthcare costs incurred/saved 
Figure A6: Example logistic curves
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(using unit health costs and utilities for each country 
obtained from our data synthesis), with the estimated 
effectiveness of the programmes. Determining whether 
a past HIV programme is cost-effective is dependent on 
country-specific thresholds. Appropriate thresholds for 
each country were determined after consultation with 
in-country stakeholders. 
Future impact of HIV programmes and 
optimal allocation of resources 
To investigate the potential impact of future HIV 
prevention programmes we run model projections 
for each scenario. Specific programme options are 
investigated but are based on core prevention methods 
(harm reduction), along with programmes based 
on using antiretroviral treatment as prevention in 
combination with other programmes. We then compare 
projections where parameters and funding remain 
at current values and calculate the annual incidence, 
the number of infections averted, and the total cost 
required for each scenario. 
Prevtool is used to determine the optimal allocation 
of funding using an adaptive stochastic linear 
gradient-descent optimisation method. This calculates 
the allocation of funding to programmes with the 
minimum total infections, minimum prevalence, 
minimum AIDS-related deaths, or maximum DALYs 
saved. It is also possible to invert this analysis and 
calculate the minimum spend required to achieve a 
particular target in terms of one of those quantities.
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Annex 2. Data inputs42 
Summary of costs and unit costs
National spending on AIDS in Tajikistan was examined 
by major funding sources with the use of national 
42 All data presented were verified by the RAC.
statistics, sector reports, and data reported by public 
health service institutions for the years between 2008 
and 2013. Standard accountancy estimation methods 
were used to generate a complete dataset of national 
spending on AIDS. Costs were broken down by 
financing sources, agents, service providers, AIDS 
spending categories, and beneficiary populations using 
functional NASA classifications and definitions. Data 
collection covered spending on AIDS response funded 
from domestic public and international funding sources.
Table A2: Budget for the national HIV programme by programme components
2012 budget in $ 2013 budget in $
HIV spending TOTAL 12,715,924 14,077,893
Prevention SUBTOTAL 5,752,333 7,186,761
Communication for social and behaviour change (BCC) 913,777 270,702 
Community mobilization 856,309 886,404 
HIV testing and counselling (HTC) 387,383 362,155 
Programmatic interventions for vulnerable and accessible population 181,923 295,655 
Prevention – youth in school 298,843 362,977 
Prevention – youth out-of-school 186,713 356,561 
Prevention of HIV transmission aimed at PLHIV 47,222 69,954 
Prevention programmes for key target populations (PWID, SW, MSM) 1,497,212 2,564,282 
Prevention of HIV transmission at the workplace 139,872 8,711
Prevention, diagnosis and treatment of STI for general population 207,496 733,241 
PMTCT not disaggregated by intervention 631,507 799,744 
Blood safety 404,076 459,549 
Post-exposure prophylaxis 0 16,826 
Care and Treatment SUBTOTAL 2,170,198 1,422,283
Provider initiated testing and counselling 177,351 277,130 
OI prophylaxis and treatment 319,368 56,298 
ART not disaggregated neither by age nor by line of treatment 716,681 909,788 
Specific HIV-related lab monitoring 295,165 110,167 
Care and treatment not disaggregated by intervention 661,633 68,900 
Programme management SUBTOTAL 3,229,888 3,458,515
Planning, coordination and programme management 1,275,059 1,286,787
Administration and transaction costs associated with managing and 
disbursing funds
263,316 362,731
Monitoring and evaluation 180,649 204,827
SuStainable Financing oF national HiV ReSponSeS 41
ANNEx
Table A2: Budget for the national HIV programme by programme components (cont.)
Serological surveillance 383,308 487,073
Upgrading and construction of infrastructure 356,932 362,496
Programme management and admin not disaggregated by 
intervention
770,624 754,601
Human resources SUBTOTAL 1,376,444 1,470,904
Monetary incentives for HR not broken by staff 943,695 1,033,037
Training 393,417 298,035
‘Human resources’, not disaggregated by type 39,332 139,832
Orphans and vulnerable children (OVC) 0 2,000
OVC, not broken down by type 0 2,000
Social protection SUBTOTAL 28,632 109,434
Social protection through in-kind benefits 28,632 109,434
Enabling environment SUBTOTAL 86,888 223,574
Advocacy 17,528 42,511 
Human rights programmes 28,581 52,791 
AIDS-specific institutional development 25,000 35,923 
AIDS-specific programmes focused on women 8,500 0 
Programmes to reduce gender-based violence 3,958 0 
Activity on enabling environment not elsewhere classified 3,321 92,349 
HIV-related research SUBTOTAL 71,541 204,422
Clinical research 5,837 9,292 
Behavioural research 29,037 165,130 
HIV and AIDS related research not disaggregated by type 36,667 30,000 
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Table A13: Biological constants
Interaction-related transmissibility (% per act): Male & female (insertive) 0.06 (0.01-0.5)
Male & female (receptive) 0.09 (0.05-1.00)
Male & male (insertive) 0.06 ((0.015-1.5)
Male & male (receptive) 0.1 (0.048-2.9)
Injecting 0.4 (0.03-5.0)
Mother-to-child 35 (20-50)
Disease-related transmissibility CD4(500) 4.0 (1.2-5.0)
CD4(350,499) 1.0 (0.8-1.2)
CD4(200,349) 1.0 (0.8-1.2)
CD4(<200) 3.8 (3.6-4.0)
Treatment 0.2 (0.02-0.5)
Disease progression rate: (% per year) CD4 (500) to CD4 (350,499) 24.5 (22.6-26.4)
CD4 (350,499) to CD4 (200,349) 51.0 (47.0-55.0)
CD4 (200,349) to CD4 (<200) 51.0 (47.0-55.0)
Treatment recovery rate: (% per year) CD4 (350,500) to CD4 (>500) 45.0 (14.0-93.0)
CD4(200,349) to CD4 (350,500) 70.0 (29.0-111.0)
CD4 (<200) to CD4 (200,349) 36.0 (28.0-43.0)
Death rate: (% mortality per year) Background 1.4 (0.9-2.0)
Injecting 1.0 (0.7-1.2)
CD4 (500) 0.052 (0.035-0.068)
CD4 (350,500) 0.128 (0.092-0.164)
CD4 (200,349) 1.1 (0.2-2.0)
CD4 (<200) 50.0 (40.0-66.0)
Treatment (CD4<200) 4.00 (1.0-10.0)
Treatment failure rate: (% per year) 1st-line 4.5 (3.0-6.0)
2nd-line 4.5 (3.0-6.0)
Efficacy/change in transmissibility due to: Condom (%) 80.0 (60.0-99.0)
Circumcision (%) 60.0 (50.0-65.0)
Diagnosis (%) 1.0 (0.0-60.0)
STI cofactor increase (%) 700.0 (100.0-1000.0)
Syringe cleaning (%) 75.0 (70.0-80.0)
Methadone (%) 95.0 (90.0-99.0)
PMTCT (%) 78.0 (40.0-99.0)
Treatment risk compensation (%) 100.0 (95.0-200.0)
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Table A14: Partnerships
LRM LRF SW MSM PWID PI LM
Regular sexual 
interactions
LRM  1     
LRF  1       
SW        
MSM     1    
PWID  1 1     
PI  1 1     
LM  1 1     
LRM LRF SW MSM PWID PI LM
Casual sexual 
interactions
LRM  1 1     
LRF        
SW        
MSM        
PWID  1 1     
PI  1 1     
LM  1 1     
LRM LRF SW MSM PWID PI LM
Other sexual 
interactions
LRM   1     
LRF        
SW        
MSM    1    
PWID   1     
PI   1     
LM   1     
LRM LRF SW MSM PWID PI LM
Injecting 
interactions
LRM        
LRF        
SW        
MSM        
PWID     1 1  
PI     1 1  
LM        
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Sustainable Financing of National HIV Responses
Get to zero
new HIV infections
Get to zero 
AIDS-related deaths Get to zero
discrimination
Get to zero
discrimination
Get to zero
discrimination
End the epidemic
threat of AIDS
End the epidemic
threat of AIDS
Universal access
to HIV services
Get to zero
new HIV infections
